Core Insights - The Phase 3 PHOENYCS GO study results indicate that dapirolizumab pegol (DZP) shows significant clinical improvements in disease activity for patients with moderate-to-severe systemic lupus erythematosus (SLE) [1][4][6] - The study demonstrated improvements in fatigue and disease activity measures, suggesting DZP's potential as a new treatment option for SLE [2][3][5] Company Overview - UCB is a global biopharmaceutical company focused on innovative medicines for severe diseases of the immune system and central nervous system, generating €6.1 billion in revenue in 2024 [13] - Biogen is a leading biotechnology company that develops innovative therapies, leveraging deep biological understanding to create new medicines [14] Clinical Study Findings - At Week 48, 40.9% of participants receiving DZP achieved low disease activity compared to 19.6% in the standard of care (SOC) group, with significant differences noted as early as Week 12 [6][7] - Improvements in fatigue were quantified, with the DZP group showing a change from baseline of 8.9 in FACIT-Fatigue scores versus 5.2 in SOC alone [5] - The safety profile of DZP was generally favorable, with treatment-emergent adverse events (TEAEs) occurring in 82.6% of DZP participants compared to 75.0% in SOC [8] Future Developments - A second Phase 3 trial, PHOENYCS FLY, is ongoing to further confirm the efficacy and safety of dapirolizumab pegol in SLE [9]